Stay updated on Nivolumab+Radiation±Ipilimumab in NSCLC Brain Metastases Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Radiation±Ipilimumab in NSCLC Brain Metastases Clinical Trial page.

Latest updates to the Nivolumab+Radiation±Ipilimumab in NSCLC Brain Metastases Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedAdded a new Locations section with Texas as a listed site. Removed the old Texas Locations heading and the HHS Vulnerability Disclosure footer link; the page revision will now show as v3.3.3.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check41 days agoChange DetectedRevision: v3.3.2 replaces v3.2.0; the update appears to be a minor frontend/backend change that does not alter the study information.SummaryDifference0.0%

- Check48 days agoChange Detected- Added a new 'Last Update Posted (Estimated)' timestamp (2025-11-07) on the Study Details page. - Removed the site-wide government funding status notice.SummaryDifference0.5%

- Check55 days agoChange DetectedThe page shows routine timestamp updates in November 2025 and deletions from May 2025, with no substantive changes to the study design, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check62 days agoChange DetectedThe new screenshot shows only cosmetic layout adjustments and a recent timestamp update; no changes to the study design, eligibility criteria, endpoints, or listed interventions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check91 days agoChange DetectedUpgrade notice added: new government funding lapse notice with operating status and official sources; version updated from v3.1.0 to v3.2.0.SummaryDifference2%

Stay in the know with updates to Nivolumab+Radiation±Ipilimumab in NSCLC Brain Metastases Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Radiation±Ipilimumab in NSCLC Brain Metastases Clinical Trial page.